Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Seekingalpha doesn't seem to be aware that Lexaria has canceled the deal with GP Holdings. News release Sept. 28.
"Finally, Lexaria announces it has canceled the contract announced on April 25 with GP Holdings LLC due to ongoing delays and non-performance."
Interview with Terry Donnely of Hill Street Beverages
https://www.facebook.com/WhatSheSaidTalk/posts/1866364873412700?__xts__%5B0%5D=68.ARAV82m8eq-qG5TpQ7gvOd86KZ2vceDXXOqcAOWxV0NykalPukPhsp7m8md5Ubj2D71VVtVWXcBhj3wRxpuBZ_uGZDeYF74z3a7hOD9eTKd8Gr9yk_gIDirAA0RrXJG8qRNJdCCUsigolFN3PSobcbEKvoPSvUkGcBH_-6q-Tn76b7Pl8yqBVskSEo6RdZK6SPeL-TyvOiVkFBiMKfu1UMV5xgE&__tn__=C-R
I'm not trying to predict the future, just rehashing what has happened. I don't think we've failed yet, but the lack of any significant deals concerns me.
To be fair it looks like Cannfections may still be an active licensee
https://www.cannfections.ca/
Also Biolog Inc.
https://investingnews.com/daily/resource-investing/agriculture-investing/cannabis-investing/redfund-capital-corp-funds-biolog-inc/
Category Killer - Licensees
Remember Timeless Herbalcare-gone; Hempco LOI-killed when Aurora took over; GP Holdings (Growpacker)- deal recently canceled for nonperformance; Biolog-unknown; Cannfections-unknown.
The only licensees now mentioned anywhere by Lexaria are Hill Street Beverages, and 1906 Chocolates, with 1906 being the only licensee that generates any revenue at all.
We've failed to make a deal with any of the marijuana or hemp producers and we've also failed to make a deal with any major beverage producers with everybody and their dog coming out with their own infused beverages and edibles.
What is wrong with Lexaria and their technology?
201,492,00 shares issued. Not fully diluted!
Lexaria Nicotine Corp.
It sure doesn't look like there are any deals imminent regarding Nicotine.
'Since mid 2017 the Company has had discussions with several leading nicotine/tobacco companies around the world and will continue to work towards a healthier consumer nicotine sector with potential industry partners well-established in the industry.'
Well it's been over a year and nothing here indicates that negotiations are ongoing. It's a Bunka busta!
Lexaria CanPharm Corp.
'...is in active discussions related to licensing its technology to companies located in Canada, the USA, and Europe..'
Yes, well we're waiting!
Lexaria Hemp Corp.
'...in discussions with a number of companies regarding the utilization of its technology in CBD-from-hemp products for the Canadian and US markets...'
'Discussions with companies in other global markets are also underway with reportable progress expected soon.'
Yes, well we're waiting, soon can't come soon enough!
'..creation of a new brand that will be introducing a new category-killer product...'
What the hell is that? How do you kill a category?
Lexaria Pharmaceutical Corp.
No discussions underway, research and development only!
We'll be waiting and waiting! Zzzzzzzz.
Big mistake, the same message is under Nicotine and then Pharmaceuticals. Whoops!
What about the taste though? There seems to be a number of companies that can infuse cannabis into a liquid but they have to add flavoring or sugar to cover the strong taste of cannabis. I assume Canopy is using flavorings instead of sugar as they claim to be 0 calories.
GB Sciences' Dr. Andrea Small-Howard Presents Results of GB Sciences' Novel Pain Formulation Research at UCLA during CannMed 2018
2018-10-09 05:30 ET - News Release
GB Sciences' Dr. Andrea Small-Howard Presents Results of GB Sciences' Novel Pain Formulation Research at UCLA during CannMed 2018
Canada NewsWire
LAS VEGAS, Oct. 9, 2018
Dr. Small-Howard explains the mechanisms for the treatment of chronic and neuropathic pain using proprietary, cannabis-based formulations
LAS VEGAS, Oct. 9, 2018 /CNW/ -- GB Sciences, Inc. (OTCQB: GBLX) announces that their Chief Science Officer, Dr. Andrea Small-Howard (http://www.cannmedevents.com/andrea-small-howard/), will be presenting the results of GB Sciences' novel pain formulation research project during the poster session for CannMed 2018 to be held at the UCLA Luskin Conference Center from October 22nd to October 24th.
According to the conference organizers, "CannMed 2018 is a gathering of the greatest minds in medical cannabis, where they will further the convergence of medical cannabis research, treatment, and product development. The world's top medical cannabis researchers will present their latest findings with regards to the efficacy of treating a variety of conditions with cannabis. Clinicians will share compelling case studies and clinical pearls they have collected through their experience treating patients with cannabis. Cannabis industry leaders will also share how they are adopting innovative testing methods and technologies to create new products that move the industry forward."
"CannMed 2018 is the perfect venue for sharing the scientific research supporting our proprietary, cannabis-based formulations for the treatment of chronic and neuropathic pain because of the superb academic and clinical credentials of the presenters and attendees at CannMed," said Dr. Small-Howard. "GB Sciences will further be presenting information on its medical cannabis product lines in booth 202. These products are designed to be sold in Nevada and Louisiana. We hope that interested participants will visit us!"
John Poss, CEO and Chairman of GB Sciences said "We are proud to be a part of CannMed 2018. In gathering all these impressive scientists, researchers and inventors, we celebrate the future of healing. This is the inspiration for GB Sciences."
About GB Sciences, Inc.
GB Sciences, Inc. (OTCQB: GBLX) is a diverse cannabis company, focused on standardized cultivation and production methods; as well as biopharmaceutical research and development. The Company's goal is creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. To learn more about GB Sciences, Inc., go to: http://gbsciences.com.
Forward-Looking Statements
This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as "expects", "intends", "plans", "may", "could", "should", "anticipates", "likely", "believes" and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company's belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company's control. It is possible that the Company's actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company's business and financial and other results, are contained in the Company's filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.
Note: Although the Company's research and development activities are not illegal, the production and sale of cannabis products violate federal laws as they presently exist.
Contact Information
Corporate:
GB Sciences, Inc., 3550 West Teco Ave., Las Vegas, NV 89118
866-721-0297, or
Tom Arcuragi, EVP, tom@gbsciences.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/gb-sciences-dr-andrea-small-howard-presents-results-of-gb-sciences-novel-pain-formulation-research-at-ucla-during-cannmed-2018-300727357.html
SOURCE GB Sciences, Inc.
View original content to download multimedia: http://www.newswire.ca/en/releases/archive/October2018/09/c1610.html
I see the 18 month study with the NRC, National Research Council of Canada has turned into a 24 month study now.
Intangible Assets Power Growth, Acquisitions in the Pharmaceuticals Sector
https://www.investornetwork.com/news/N-D7E7C818BF363FF91E438FE5564B39
It's old news, my friend.
Dear Lexaria Subscribers,
Infusion: The 'critical piece' of the edibles puzzle
C/O Globe and Mail - Report on Business Cannabis
HIGHLIGHTS
1. Companies are racing to find technology that speeds up the effects of ingesting cannabis
2. Some firms are researching in-house, others turning to specialty companies such as Lexaria
3. Lexaria says it's in talks with several cannabis-related companies
Marijuana companies are gearing up to sell cannabis-infused food and beverages – the next phase of pot legalization in Canada expected next year – with a focus on providing products that don’t smell or taste like weed.
Companies are also scrambling to find the right technology that speeds up the effects of ingesting cannabis, similar to drinking a glass of wine or beer, to better compete with the alcohol industry.
“It’s a critical piece of the puzzle,” Jason Zandberg, an analyst at PI Financial, said of the onset and offset effects of edible cannabis products.
The goal is for consumers to feel the effects of cannabis-infused products in roughly 10-to-20 minutes, instead of an hour or more, which is the case with many edibles with tetrahydrocannabinol (THC), known for providing a "high," made at home or sold on the black market today.
“They need to nail down the ability to have consumers feel the effects,” sooner to avoid over consumption of THC, which could lead to an unpleasant experience, Mr. Zandberg said.
Industry leader Canopy Growth Corp. is working on its own in-house cannabis-delivery technology for this next market, while others are turning to specialized technology companies such as B.C.-based Lexaria Bioscience Corp. Lexaria claims its patented technology helps to improve the taste, smell and absorption of cannabis-infused products. Lexaria and others in the space are developing technology that delivers both THC and cannabidiol (CBD), the latter of which is often used for medical purposes.
It’s part of the race to develop alternative pot products after cannabis is legalized for recreational use on Oct. 17, starting with cannabis plants, seeds and oils. Health Canada is working on regulations for cannabis edibles, including food and beverages, expected to be released around mid-2019. It’s taking into consideration what it cites are the “unique potential health risks and harms that need to be carefully understood" with edibles. The regulations are expected to outline how much cannabis can be used per serving in food and drinks.
Roughly six out of 10 consumers are expected to choose edible products, including beverages when legal, according to a recent report from Deloitte. Cannabis products could potentially eat up around 15-to-20-per cent of the alcohol market, based on a study of U.S. states where it’s already legal.
It’s that threat to the alcohol market that has a growing number of beverage companies getting in on the action. International wine and beer maker Constellation Brands recently boosted its stake in Canopy Growth to 38 per cent from 10 per cent, while Molson Coors Brewing Co. struck a joint venture with HEXO Corp. (formerly known as Hydropothecary Corp.) to develop non-alcoholic, cannabis-infused beverages.
Coca-Cola Co. recently confirmed to the Globe and Mail that it’s watching the growth in the use of CBD in “wellness beverages.” Coke is among several beverage firms that have been talking with cannabis growers to learn more about the plant, according to The Globe’s reporting.
Canopy Growth CEO Bruce Linton said his company has been researching cannabis-infused beverages in-house for about three years, with a focus on consumer tastes.
“We simply looked at it and said ‘if we had consumers, how would they expect these products to be delivered, work, duration of effect and – knowing what we do about cannabis and extraction – how can we get there,?’” Mr. Linton said in a recent interview.
He wouldn't divulge any specific information about the products or technology being tested, citing competitive reasons, but said the company will be ready to launch the products when edibles are legal. “We think these experiments will yield some very interesting combinations," Mr. Linton said.
A HEXO spokesperson also declined to comment on the technology it’s using as part of its joint venture with Molson, including whether it involves an outside party.
Hill Street Beverage Co. Inc., Canada's largest alcohol-free wine and beer company, has signed an agreement with Lexaria to develop cannabis drinks, using Lexaria's DehydraTECH technology.
“Cannabis is a really stinky weed,” Hill Street CEO Terry Donnelly SAID. “With the Lexaria process, the infused product was virtually indistinguishable," based on testing to date.
Lexaria says its technology, created specifically for use in cannabis products, not only masks the taste and smell of cannabis but also controls how it's absorbed in the body. Its process includes mixing cannabis oil with fatty acids derived from sunflower oil. The combination is put through the company's specialized dehydration process to draw out the benefits. Once in the body, the formulation works with existing body functions that absorb fatty acids and channels them away from the liver for rapid access to the bloodstream.
The company says its technology enables cannabis in the products to be absorbed in about 10-to-20 minutes, versus 60 to 120 minutes for some cannabis-based edibles today. The effects last for about two-to-three hours.
The company says its technology is also an alternative to sugars and chemicals that are often used to placate taste and odours in certain food and beverages.
“We are focused on making ingestible or edible bioactive substances taste better, smell better, act faster and enhance potency,” says Lexaria president John Docherty, a trained pharmacologist and toxicologist, who is also the former president and chief operation officer of pharmaceutical firm Helix BioPharma Corp.
The company’s focus is on licensing its technology to third parties for use in their products. An example is a Colorado-based company that sells the 1906 brand of chocolate, which is infused with THC using Lexaria’s technology, as well as Los Angeles-based Biolog, Inc., which makes food and beverages with cannabis. Lexaria also has an agreement with the newly created Cannfections Group Inc. in Canada, which plans to make cannabis-infused chocolate, gummies and other candy.
Mr. Doherty says the company has “numerous other discussions underway” with small and large industry players following its business model in the lead-up to the legalization of edible cannabis products expected next year.
For all the latest news and updates while on the go just text "lexaria" to 76000.
Are you on Twitter, Facebook or Google+? Do not forget to look us up or just click on the buttons below. Give us a follow and a like. Also do not forget to check out our website for all the latest news and updates on Lexaria Bioscience Corp.
This email is sent by Lexaria Bioscience Corp., 156 Valleyview Rd, Kelowna, BC V1X 3M4. See www.lexariabioscience.com for more information.
D
No, I don't see anything about increased bioavailability and crossing the blood, brain barrier which should be critical in a trial for a degenerative brain disease like Parkinson's. They probably see Lexaria as a competitor in this space and wouldn't consider their tech.
GB Sciences (GBLX) to use Catalent (Zydis) fast dissolve tablets in their upcoming Parkinsons clinical trial. I don't know how this tech compares to LXRP.
https://www.stockwatch.com/News/Item.aspx?bid=U-C3864-U%3aGBLX-20180926&symbol=GBLX®ion=U
https://www.catalent.com/index.php/offerings/A-Z-Offerings/zydis
Interesting discussion on GW Pharma's Epidiolex on Facebook, I was corrected when I said GW have a patent on CBD.
"They have a patent for the delivery method, not on the molecule."
And I was also corrected when I said that Epidiolex was pure pharma grade CBD.
"Not quite, it's pure CBD in a proprietary delivery system. The dehydrated alcohol is unique and increases bioavailability."
What's interesting is that the delivery system seems very similar to Lexarias's except using alcohol instead of vegetable oil. Does this somehow devalue LXRP if you can copy their tech using a different substance? One obvious plus is that oil is natural, alcohol not so much.
A buyout can only happen if Chris Bunka agrees to the price, as he has control. Which is a real positive.
Good News for Edible Nicotine
https://www.cnn.com/2018/09/12/health/fda-e-cigarette-juul-crackdown-bn/index.html
Hill Street Beverages Profiled, LXRP mention
https://view.joomag.com/canadian-cannainvestor-magazine-september-2018/0837911001533263872/p282?short
Hill Street Beverages
Polymer Technology This is not natural at all! Chemicals!
http://www.invisicare.com/technology.html
Here's another excerpt from the Lighthouse prospectus, they're seeking a listing on the CSE in early 2019. They're pretty vague about the two patents. One patent appears to be for Ovation formerly “Invisicare”, Patented Pharmaceutical Drug Delivery technology.
BUSINESS EVOLUTION
Although Lighthouse was formed in February 2016, the genesis of Lighthouse was developed from the founders initial Nevada developments in January 2014 where they secured Cultivation, Manufacturing and Dispensary licenses. Over the course of 2015 and 2016 the team developed and opened Las Vegas Releaf, the first legal dispensary in the City of Las Vegas, and Silver State Wellness a marijuana infused products manufacturer in Un-incorporated Clark County.
In parallel, members elected to branch off to establish a position in the California market as well as an intellectual property or “Brands” focused position in the emerging cannabis industry. These parallel efforts resulted in the creation of three independent efforts that over the course of 2017 included the establishment of a California cannabis cultivation and production, the acquisition of two (2) City of San Diego Licensed cannabis organizations, the acquisition of a wholesale and retail tea company, securing the exclusive U.S.A. patent rights to two (2) patented product platforms, the development of (5) unique brands, the acquisition of a craft beer brewery; resulting in a diversified 151,000 square foot, multi-state organization.
Reading this information one can only assume that Two-Roots is not using Lexaria's DehydraTECH as they seem to be claiming to have developed their own method of infusing cannabis that has a rapid onset similar to Lexaria's. In addition they have their own brewery so they're not using Growpacker a LXRP licensee.
First Mover Position
Lighthouse has invested two (2) years of reach and development, resulting in the procurement of the first beer,
wine and champagne de-alkalization system to enter the United States, and to support its implementation the
acquisition of a San Diego Micro Craft Brewery required to support its operation. All of which comes together in
San Diego, CA to result in the production of Two Roots Brewing Co., the world’s first non-alcoholic craft beer
infused with cannabis and formulated to emulate the effects of alcohol. Through the work of our pharmaceutical
chemist and food scientists Lighthouse has formulated Two Roots to provide onset within five to ten (5-10)
minutes, with dissipation within an hour and a half (1.5) hours.
"LXRP may also be able to deliver micro nicotine doses, as per developing FDA policies"
It's supposed to be a relatively easy process that costs only pennies per dose. It may actually save companies money as they will be able to use far less of whatever molecule they are using.
"...with a number of licensing agreements currently in the works through its four wholly owned subsidiaries serving the nicotine, hemp, pharmaceutical and cannabis industries."
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Offers Via
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Offers Viable and Effective Alternatives for Nicotine Delivery
- Results from second in vivo study of 2018 a success
- DehydraTECH™ had a 90.2 percent greater absorption rate in the first 10 minutes
- Clients are improving high-quality products through the enhancement of this drug delivery platform
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a company focused on developing and out-licensing its disruptive drug delivery platform DehydraTECH™, recently announced the results of its second in vivo study of 2018 evaluating this edible technology’s use as a nicotine delivery system (http://nnw.fm/dmD2T).
The study was carried out by a third-party laboratory, which discovered that the absorption of nicotine was significantly greater when delivered by DehydraTECH™. In comparison with the tested control, the DehydraTECH™ system delivered a 90.2 percent greater absorption rate in the first 10 minutes. Because smoking gets the drug into the body so quickly, the speed of absorption for this edible form of nicotine delivery is very important in the overall success of providing a smoking alternative.
Lexaria’s DehydraTECH™ drug delivery platform offers a solution to the high numbers of smoking-related deaths and diseases. According to the U.S. Centers for Disease Control and Prevention (CDC), six million people die every year worldwide as a result of smoking, and 30 times that are living with serious illnesses related to a history of smoking (http://nnw.fm/2CnPX).
This disruptive drug delivery platform has multiple uses. Lexaria out-licenses DehydraTECH™ to entities whose goal is to deliver healthier ingestion methods of cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine and other molecules. With eight patents and nearly 50 more pending worldwide, Lexaria is enhancing the high-quality products of clients, not competing with them. Clients are improving upon high-quality products by increasing absorption rates, as well as improving taste and smell of the final product.
Clients are utilizing this edible technology in chocolates, beverages, dissolvable infusion products and more. Eighty percent of the company’s total revenue in 2018 is anticipated to come from the licensing of DehydraTECH™, with a number of licensing agreements currently in the works through its four wholly owned subsidiaries serving the nicotine, hemp, pharmaceutical and cannabis industries.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Cannabis infused beverages or edibles are not legal in Canada yet, so Hill Street is not selling any. They do have alcohol free wines and beers that are supposed to be very good. I haven't tried any, I live in Yukon and haven't seen any for sale here.
https://www.hillstreetbevco.com/shop
Lexaria Delivers Across the Blood Brain Barrier
https://www.potnetwork.com/news/delivering-cannabis-over-blood-brain-barrier
I think Hill Street (BEER) could be a real takeover candidate, you don't necessarily need a grower, you can buy the oil from any number of companies.
https://www.bnnbloomberg.ca/video/hill-street-beverage-co-looks-to-alcohol-alternatives-with-cannabis-infused-drinks~1472019
It's going to be a Wild Wild Week of Weed
https://www.bloomberg.com/news/videos/2018-08-24/canadian-marijuana-stocks-jump-on-report-diageo-discussing-deal-video
Everyone and their dog wants to bring a cannabis-infused beverage to market but as the interview notes, the problem is the long time for the effects to hit you and scientists are scrambling to solve a problem Lexaria already has the answer to. Nothing but upside for LXRP from here on in!